NewsPulse
← All stories
Science3 days ago· 1 min read

Scientists Find Gut-Heart Connection That May Explain Sleep Apnea's Cardiovascular Risk

Researchers discovered a surprising link between sleep apnea and heart disease involving the gut, finding that disabling a bile acid receptor reduced plaque buildup in mice, offering potential new treatment pathways.

New Understanding of Sleep Apnea and Heart Disease

A surprising gut-heart connection may help explain why sleep apnea increases the risk of cardiovascular disease. This discovery identifies a previously unknown biological pathway linking respiratory sleep disorders to heart health, potentially explaining a long-observed clinical correlation.

The Bile Acid Receptor Connection

In mice, disabling a bile acid receptor called FXR sharply reduced plaque buildup, opening the door to potential new treatments targeting the gut-cardiac axis. Bile acid receptors play crucial roles in metabolism and immune regulation, and this research reveals their unexpected importance in the cardiovascular consequences of sleep apnea.

Why This Matters

Sleep apnea affects millions of people worldwide and is a well-established risk factor for heart attacks, strokes, and other cardiovascular events. However, the precise biological mechanisms connecting breathing interruptions during sleep to heart disease have remained poorly understood. This research provides a mechanistic framework—involving gut signaling through bile acid pathways—that could explain this dangerous association.

Therapeutic Possibilities

The findings suggest that targeting the FXR receptor or related gut signaling pathways might offer a novel approach to protecting heart health in sleep apnea patients. Unlike traditional treatments like continuous positive airway pressure (CPAP) machines, which address breathing directly, these new approaches could complement existing therapies by addressing the underlying cardiovascular risk. Researchers are now planning further studies to understand how sleep disruption affects the gut-heart axis and to identify candidate drugs that could modulate this pathway effectively.

Sources

Related coverage